Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations
Non Small Cell Lung Cancer
DRUG: Adebrelimab|DRUG: paclitaxel for injection (albumin bound)|DRUG: Cisplatin or Carboplatin
Pathological complete response rate, pCR rate, the proportion of patients achieved pathologic complete response (lung and lymph node without tumor residual assessed by pathology review), at 12 months
Major pathologic response rate, MPR rate, the proportion of patients achieved pathologic complete response (lung and lymph node â‰¤10% tumor residual assessed by pathology review), 12 months|R0 rate, the proportion of patients achieved R0(No residue under the microscope after resection), 12 months|Event Free Survival, EFS, the time length from the first dose to any prescriptive events, up to 5 years|Overall Survival, OS, the time length from the date of the first dose to the date of death., up to 5 years|Objective response rate, ORR, the proportion of patients achieved complete or partial response, 12 months|Adverse Events, AEs, up to 5 years
This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations